{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T20:52:49Z","timestamp":1779396769288,"version":"3.53.1"},"reference-count":87,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cutaneous lupus erythematosus (CLE) is a complex autoimmune disease often characterized by a multitude of skin findings. CLE is generally classified into three main categories: acute CLE, subacute CLE and chronic CLE. The current therapeutic guidelines for CLE include counselling patients on general measures and medication regimens. Treatment options include optimized photoprotection, avoidance of environmental triggers, corticosteroids, topical and systemic immunomodulators, and antimalarials. To date, no biologic medications (i.e. monoclonal antibodies, mAbs) are approved for CLE. The first mAb for the treatment of both systemic lupus erythematosus (SLE) and active lupus nephritis was belimumab, and was approved for these diseases in 2011 and 2020, respectively. Belimumab is a specific inhibitor of B-lymphocyte stimulator. Anifrolumab, a type I interferon receptor antagonist, was approved in 2021 for SLE. Other mAbs with different targets, including a novel biologic that inhibits blood dendritic cell antigen 2, are currently under investigation for CLE. This review will describe the general treatment landscape for CLE. Selected studies related to these various mAbs will be discussed, as well as their safety profiles and efficacies demonstrated in clinical trials. Biologic medications can potentially augment the number of treatment options for patients living with CLE.<\/jats:p>","DOI":"10.1093\/ced\/llae374","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T16:40:51Z","timestamp":1725727251000},"page":"314-322","source":"Crossref","is-referenced-by-count":3,"title":["Monoclonal antibodies for the management of cutaneous lupus erythematosus: an update on the current treatment landscape"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9452-3712","authenticated-orcid":false,"given":"Alexander J","family":"Jafari","sequence":"first","affiliation":[{"name":"Department of Dermatology, UTHealth McGovern Medical School , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"McGee","sequence":"additional","affiliation":[{"name":"UTHealth McGovern Medical School , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Klimas","sequence":"additional","affiliation":[{"name":"Department of Dermatology, UTHealth McGovern Medical School , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide A","family":"Hebert","sequence":"additional","affiliation":[{"name":"Department of Dermatology, UTHealth McGovern Medical School , Houston, TX ,","place":["USA"]},{"name":"Department of Pediatrics, UTHealth McGovern Medical School , Houston, TX ,","place":["USA"]},{"name":"Department of Dermatology, MD Anderson Cancer Center , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"key":"2025012715565710500_llae374-B1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/acr.22502","article-title":"Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States","volume":"67","author":"Jarukitsopa","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025012715565710500_llae374-B2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025012715565710500_llae374-B3","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s10067-016-3235-8","article-title":"Genetic association study of systemic lupus erythematosus and disease subphenotypes in European populations","volume":"35","author":"Ruiz-Larra\u00f1aga","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2025012715565710500_llae374-B4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1600-0625.2009.00982.x","article-title":"Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus","volume":"19","author":"J\u00e4rvinen","year":"2010","journal-title":"Exp Dermatol"},{"key":"2025012715565710500_llae374-B5","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1136\/ard.2011.154104","article-title":"Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus","volume":"70","author":"Sanchez","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2025012715565710500_llae374-B6","doi-asserted-by":"crossref","first-page":"e14212","DOI":"10.1371\/journal.pone.0014212","article-title":"Polymorphisms of the ITGAM gene confer higher risk of discoid cutaneous than of systemic lupus erythematosus","volume":"5","author":"J\u00e4rvinen","year":"2010","journal-title":"PLOS ONE"},{"key":"2025012715565710500_llae374-B7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/gene.2009.39","article-title":"Recent insights into the genetic basis of systemic lupus erythematosus","volume":"10","author":"Moser","year":"2009","journal-title":"Genes Immun"},{"key":"2025012715565710500_llae374-B8","doi-asserted-by":"crossref","first-page":"e127291","DOI":"10.1172\/jci.insight.127291","article-title":"The female-biased factor VGLL3 drives cutaneous and systemic autoimmunity","volume":"4","author":"Billi","year":"2019","journal-title":"JCI Insight"},{"key":"2025012715565710500_llae374-B9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni.3643","article-title":"A gene network regulated by the transcription factor VGLL3 as a promoter of sex-biased autoimmune diseases","volume":"18","author":"Liang","year":"2017","journal-title":"Nat Immunol"},{"key":"2025012715565710500_llae374-B10","doi-asserted-by":"crossref","first-page":"916011","DOI":"10.3389\/fmed.2022.916011","article-title":"The genetic landscape of cutaneous lupus erythematosus","volume":"9","author":"Chen","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025012715565710500_llae374-B11","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00296-022-05183-4","article-title":"Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis","volume":"42","author":"Fatoye","year":"2022","journal-title":"Rheumatol Int"},{"key":"2025012715565710500_llae374-B12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12016-009-8192-4","article-title":"The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies","volume":"40","author":"Weckerle","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025012715565710500_llae374-B13","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1177\/0961203318777103","article-title":"Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark","volume":"27","author":"Petersen","year":"2018","journal-title":"Lupus"},{"key":"2025012715565710500_llae374-B14","doi-asserted-by":"crossref","first-page":"e897987","DOI":"10.3389\/fmed.2022.897987","article-title":"The burden of living with cutaneous lupus erythematosus","volume":"9","author":"Drenkard","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025012715565710500_llae374-B15","first-page":"77","article-title":"Genetic background of cutaneous forms of lupus erythematosus: update on current evidence","volume":"45","author":"Osmola","year":"2004","journal-title":"J Appl Genet"},{"key":"2025012715565710500_llae374-B16","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1002\/art.23701","article-title":"Klinefelter\u2019s syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome","volume":"58","author":"Scofield","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2025012715565710500_llae374-B17","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatology"},{"key":"2025012715565710500_llae374-B18","doi-asserted-by":"crossref","first-page":"A277","DOI":"10.1016\/j.autrev.2009.12.008","article-title":"The geoepidemiology of systemic lupus erythematosus","volume":"9","author":"Borchers","year":"2010","journal-title":"Autoimmun Rev"},{"key":"2025012715565710500_llae374-B19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of Black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl. 1","key":"2025012715565710500_llae374-B20","first-page":"i67","article-title":"The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus","volume":"56","author":"Lewis","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025012715565710500_llae374-B21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/art.22672","article-title":"A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE","volume":"57","author":"Fern\u00e1ndez","year":"2007","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025012715565710500_llae374-B22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2013.03.015","article-title":"Characterization of clinical photosensitivity in cutaneous lupus erythematosus","volume":"69","author":"Foering","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2025012715565710500_llae374-B23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/archdermatol.2011.342","article-title":"Impact of smoking in cutaneous lupus erythematosus","volume":"148","author":"Piette","year":"2012","journal-title":"Arch Dermatol"},{"key":"2025012715565710500_llae374-B24","doi-asserted-by":"crossref","first-page":"102707","DOI":"10.1016\/j.jaut.2021.102707","article-title":"Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus","volume":"123","author":"Lu","year":"2021","journal-title":"J Autoimmun"},{"key":"2025012715565710500_llae374-B25","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.jaad.2010.06.018","article-title":"Cutaneous lupus erythematosus: update of therapeutic options part I","volume":"65","author":"Kuhn","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2025012715565710500_llae374-B26","doi-asserted-by":"crossref","first-page":"941003","DOI":"10.3389\/fmed.2022.941003","article-title":"An update on the management of refractory cutaneous lupus erythematosus","volume":"9","author":"Verdelli","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025012715565710500_llae374-B27","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4103\/2229-5178.142483","article-title":"Side-effects of topical steroids: a long overdue revisit","volume":"5","author":"Coondoo","year":"2014","journal-title":"Indian Dermatol Online J"},{"key":"2025012715565710500_llae374-B28","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/BOR.0000000000000704","article-title":"Treatment of cutaneous lupus erythematosus: current approaches and future strategies","volume":"32","author":"Shi","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"2025012715565710500_llae374-B29","volume-title":"StatPearls","author":"Hodgens","year":"2024"},{"key":"2025012715565710500_llae374-B30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N Engl J Med"},{"key":"2025012715565710500_llae374-B31","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.1992.tb14851.x","article-title":"Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine","volume":"127","author":"Ruzicka","year":"1992","journal-title":"Br J Dermatol"},{"key":"2025012715565710500_llae374-B32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","article-title":"Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection","volume":"8","author":"Fishbein","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025012715565710500_llae374-B33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00403-018-1808-x","article-title":"Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review","volume":"310","author":"Florek","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"2025012715565710500_llae374-B34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrd3436","article-title":"Belimumab","volume":"10","author":"Sanz","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2025012715565710500_llae374-B35","volume-title":"Belimumab treatment for adults with systemic lupus erythematosus: a review of clinical effectiveness, cost-effectiveness, and guidelines","author":"Chao","year":"2018"},{"key":"2025012715565710500_llae374-B36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40257-023-00774-8","article-title":"Cutaneous lupus erythematosus: an update on pathogenesis and future therapeutic directions","volume":"24","author":"Niebel","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2025012715565710500_llae374-B37","doi-asserted-by":"crossref","first-page":"15978","DOI":"10.1074\/jbc.274.23.15978","article-title":"Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-\u03baB, and c-jun NH2-terminal kinase","volume":"274","author":"Mukhopadhyay","year":"1999","journal-title":"J Biol Chem"},{"key":"2025012715565710500_llae374-B38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nbt.2076","article-title":"The discovery and development of belimumab: the anti-BLyS-lupus connection","volume":"30","author":"Stohl","year":"2012","journal-title":"Nat Biotechnol"},{"key":"2025012715565710500_llae374-B39","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1073\/pnas.97.7.3370","article-title":"Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice","volume":"97","author":"Khare","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025012715565710500_llae374-B40","doi-asserted-by":"crossref","first-page":"103262","DOI":"10.1016\/j.autrev.2022.103262","article-title":"Circulating and skin biopsy-present cytokines related to the pathogenesis of cutaneous lupus erythematosus","volume":"22","author":"Erazo-Mart\u00ednez","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2025012715565710500_llae374-B41","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025012715565710500_llae374-B42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/0961203316670731","article-title":"Biological therapies in the treatment of cutaneous lupus erythematosus","volume":"26","author":"Presto","year":"2017","journal-title":"Lupus"},{"key":"2025012715565710500_llae374-B43","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.3899\/jrheum.150470","article-title":"Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices","volume":"42","author":"Hui-Yuen","year":"2015","journal-title":"J Rheumatol"},{"key":"2025012715565710500_llae374-B44","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/0961203316682097","article-title":"Belimumab for the treatment of recalcitrant cutaneous lupus","volume":"26","author":"Vashisht","year":"2017","journal-title":"Lupus"},{"key":"2025012715565710500_llae374-B45","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/acr.25058","article-title":"Improvement in cutaneous lupus erythematosus after twenty weeks of belimumab use: a systematic review and meta-analysis","volume":"75","author":"Kneeland","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025012715565710500_llae374-B46","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025012715565710500_llae374-B47","doi-asserted-by":"crossref","first-page":"108811","DOI":"10.1016\/j.intimp.2022.108811","article-title":"Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: a systematic review and meta-analysis of randomised controlled trials","volume":"109","author":"Xu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"2025012715565710500_llae374-B48","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2665-9913(20)30355-6","article-title":"Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-\u00adcontrolled, phase 4 trial","volume":"3","author":"Sheikh","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025012715565710500_llae374-B49","doi-asserted-by":"crossref","first-page":"e001629","DOI":"10.1136\/rmdopen-2021-001629","article-title":"Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7\u2005years in patients with systemic lupus erythematosus from Japan and South Korea","volume":"7","author":"Tanaka","year":"2021","journal-title":"RMD Open"},{"key":"2025012715565710500_llae374-B50","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/bdr2.2091","article-title":"Belimumab use during pregnancy: interim results of the belimumab pregnancy registry","volume":"115","author":"Juliao","year":"2023","journal-title":"Birth Defects Res"},{"key":"2025012715565710500_llae374-B51","doi-asserted-by":"crossref","first-page":"916134","DOI":"10.3389\/fmed.2022.916134","article-title":"Influence of socio-\u00addemographic factors in patients with cutaneous lupus erythematosus","volume":"9","author":"Walker","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025012715565710500_llae374-B52","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.autrev.2017.02.005","article-title":"Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus","volume":"16","author":"Parodis","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2025012715565710500_llae374-B53","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/14712598.2018.1494719","article-title":"Smoking reduces the efficacy of belimumab in mucocutaneous lupus","volume":"18","author":"Parodis","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"2025012715565710500_llae374-B54","doi-asserted-by":"crossref","first-page":"e000261","DOI":"10.1136\/lupus-2018-000261","article-title":"Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus","volume":"5","author":"Riggs","year":"2018","journal-title":"Lupus Sci Med"},{"key":"2025012715565710500_llae374-B55","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1111\/ced.15335","article-title":"Anifrolumab for treatment of refractory cutaneous lupus erythematosus","volume":"47","author":"Blum","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"2025012715565710500_llae374-B56","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"2025012715565710500_llae374-B57","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/annrheumdis-2018-213197","article-title":"Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa","volume":"77","author":"Sarkar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025012715565710500_llae374-B58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2025012715565710500_llae374-B59","first-page":"e39553","article-title":"Role of anifrolumab in refractory cutaneous manifestations of lupus erythematosus: a case series and literature review","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"key":"2025012715565710500_llae374-B60","doi-asserted-by":"crossref","first-page":"980079","DOI":"10.3389\/fimmu.2022.980079","article-title":"Belimumab or anifrolumab for systemic lupus erythematosus? A risk\u2013benefit assessment","volume":"13","author":"Kirou","year":"2022","journal-title":"Front Immunol"},{"key":"2025012715565710500_llae374-B61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdcr.2023.04.024","article-title":"Successful treatment of severe chronic cutaneous lupus with anifrolumab: a series of 6 cases","volume":"37","author":"Kowalski","year":"2023","journal-title":"JAAD Case Rep"},{"key":"2025012715565710500_llae374-B62","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025012715565710500_llae374-B63","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025012715565710500_llae374-B64","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/13543784.2023.2212154","article-title":"Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus","volume":"32","author":"Cho","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"2025012715565710500_llae374-B65","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2025012715565710500_llae374-B66","first-page":"100299","article-title":"From monogenic lupus to TLR7\/MyD88-targeted therapy","volume":"3","author":"Wang","year":"2022","journal-title":"Innovation"},{"key":"2025012715565710500_llae374-B67","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology"},{"key":"2025012715565710500_llae374-B68","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025012715565710500_llae374-B69","doi-asserted-by":"crossref","first-page":"151899","DOI":"10.1016\/j.imbio.2019.151899","article-title":"Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders","volume":"225","author":"Chand Dakal","year":"2020","journal-title":"Immunobiology"},{"key":"2025012715565710500_llae374-B70","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/rheumatology\/keh443","article-title":"Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab","volume":"44","author":"Tokunaga","year":"2005","journal-title":"Rheumatology"},{"key":"2025012715565710500_llae374-B71","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/1744666X.2014.878649","article-title":"Ustekinumab for the treatment of psoriatic arthritis","volume":"10","author":"Wofford","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"2025012715565710500_llae374-B72","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/ibd\/izaa236","article-title":"Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2\/3 studies","volume":"27","author":"Sandborn","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2025012715565710500_llae374-B73","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/archdermatol.2011.185","article-title":"Successful treatment of subacute lupus erythematosus with ustekinumab","volume":"147","author":"De Souza","year":"2011","journal-title":"Arch Dermatol"},{"key":"2025012715565710500_llae374-B74","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1111\/ijd.14773","article-title":"Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus","volume":"59","author":"Mazgaj","year":"2020","journal-title":"Int J Dermatol"},{"key":"2025012715565710500_llae374-B75","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3899\/jrheum.210805","article-title":"Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase II open-label extension study","volume":"49","author":"van Vollenhoven","year":"2022","journal-title":"J\u00a0Rheumatol"},{"key":"2025012715565710500_llae374-B76","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"key":"2025012715565710500_llae374-B77","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"van Vollenhoven","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025012715565710500_llae374-B78","first-page":"4","article-title":"Janus kinase and tyrosine kinase inhibitors in dermatology: a review of their utilization, safety profile and future applications","volume":"27","author":"Shalabi","year":"2022","journal-title":"Skin Ther Lett"},{"key":"2025012715565710500_llae374-B79","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fimmu.2020.00344","article-title":"Selective Janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions","volume":"11","author":"Fetter","year":"2020","journal-title":"Front Immunol"},{"key":"2025012715565710500_llae374-B80","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaad.2022.12.037","article-title":"Management of cutaneous lupus erythematosus with Janus kinase inhibitor therapy: an evidence-based review","volume":"89","author":"Abduelmula","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025012715565710500_llae374-B81","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archdermatol.2011.290","article-title":"Tissue eosinophilia: not an indicator of drug-induced subacute cutaneous lupus erythematosus","volume":"148","author":"Hillesheim","year":"2012","journal-title":"Arch Dermatol"},{"key":"2025012715565710500_llae374-B82","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jdcr.2016.05.022","article-title":"Lupus erythematosus tumidus: a case and discussion of a rare entity in black patients","volume":"2","author":"Gallitano","year":"2016","journal-title":"JAAD Case Rep"},{"key":"2025012715565710500_llae374-B83","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.clindermatol.2006.07.014","article-title":"Lupus erythematosus: systemic and cutaneous manifestations","volume":"24","author":"Rothfield","year":"2006","journal-title":"Clin Dermatol"},{"key":"2025012715565710500_llae374-B84","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11882-020-00906-8","article-title":"Cutaneous lupus erythematosus: progress and challenges","volume":"20","author":"Petty","year":"2020","journal-title":"Curr Allergy Asthma Rep"},{"key":"2025012715565710500_llae374-B85","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"2025012715565710500_llae374-B86","first-page":"w20022","article-title":"Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland","volume":"149","author":"Von Kempis","year":"2019","journal-title":"Swiss Med Wkly"},{"key":"2025012715565710500_llae374-B87","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J Clin Invest"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae374\/60774072\/llae374.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae374\/60774072\/llae374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae374\/60774072\/llae374.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T15:57:28Z","timestamp":1737993448000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/2\/314\/7750703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":87,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,9,7]]},"published-print":{"date-parts":[[2025,1,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae374","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,9,7]]}}}